Literature DB >> 19372254

Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?

Tiziano Barbui1, Alessandra Carobbio, Alessandro Rambaldi, Guido Finazzi.   

Abstract

Leukocyte (WBC) count has been recently identified as an independent predictor of major thrombosis in both essential thrombocythemia (ET) and polycythemia vera (PV). However, whether leukocytosis should be simply considered a marker for vascular disease or whether elevated WBC levels actually contribute directly to causing such disorders is presently matter of many studies. By adopting epidemiologic criteria for causation, we have examined the characteristics to support this association such as (1) strength, (2) consistency, (3) specificity, (4) temporality, (5) biologic gradient, (6) plausibility, (7) experimental evidence, and (8) analogy. Our conclusion supports the notion that baseline leukocytosis in ET and PV patients adds prognostic significance to existing risk factors and that may be considered causative of vascular events. These developments could induce clinicians to incorporate WBC count into standard clinical practice. However, we need prospective clinical studies with stratification of patients according to their baseline leukocyte counts. Until such evidence is available, the decision on how to manage these patients should continue to follow conventional criteria.

Entities:  

Mesh:

Year:  2009        PMID: 19372254      PMCID: PMC2716019          DOI: 10.1182/blood-2009-02-206797

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION?

Authors:  A B HILL
Journal:  Proc R Soc Med       Date:  1965-05

2.  Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation.

Authors:  Michael J Pencina; Ralph B D'Agostino
Journal:  Stat Med       Date:  2004-07-15       Impact factor: 2.373

3.  Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera.

Authors:  Anna Falanga; Marina Marchetti; Alfonso Vignoli; Donatella Balducci; Tiziano Barbui
Journal:  Exp Hematol       Date:  2005-05       Impact factor: 3.084

4.  When and how to treat essential thrombocythemia.

Authors:  Tiziano Barbui; Guido Finazzi
Journal:  N Engl J Med       Date:  2005-07-07       Impact factor: 91.245

5.  Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.

Authors:  Roberto Marchioli; Guido Finazzi; Raffaele Landolfi; Jack Kutti; Heinz Gisslinger; Carlo Patrono; Raphael Marilus; Ana Villegas; Gianni Tognoni; Tiziano Barbui
Journal:  J Clin Oncol       Date:  2005-02-14       Impact factor: 44.544

Review 6.  Atherosclerosis--an inflammatory disease.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1999-01-14       Impact factor: 91.245

7.  C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study.

Authors:  Ioanna Tzoulaki; Gordon D Murray; Amanda J Lee; Ann Rumley; Gordon D O Lowe; F Gerald R Fowkes
Journal:  Circulation       Date:  2005-08-08       Impact factor: 29.690

8.  Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

Authors:  Claire N Harrison; Peter J Campbell; Georgina Buck; Keith Wheatley; Clare L East; David Bareford; Bridget S Wilkins; Jon D van der Walt; John T Reilly; Andrew P Grigg; Paul Revell; Barrie E Woodcock; Anthony R Green
Journal:  N Engl J Med       Date:  2005-07-07       Impact factor: 91.245

Review 9.  Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene?

Authors:  Barry S Coller
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-01-20       Impact factor: 8.311

Review 10.  Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

Authors:  Tiziano Barbui; Giovanni Barosi; Alberto Grossi; Luigi Gugliotta; Lucio N Liberato; Monia Marchetti; Maria Gabriella Mazzucconi; Francesco Rodeghiero; Sante Tura
Journal:  Haematologica       Date:  2004-02       Impact factor: 9.941

View more
  37 in total

1.  Treatment outcome in a cohort of young patients with polycythemia vera.

Authors:  Marco Ruggeri; Silvia Finotto; Stefania Fortuna; Francesco Rodeghiero
Journal:  Intern Emerg Med       Date:  2010-07-06       Impact factor: 3.397

2.  Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.

Authors:  Tiziano Barbui; Alessandra Carobbio; Guido Finazzi; Alessandro M Vannucchi; Giovanni Barosi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro Pancrazzi; Silvia Salmoiraghi; Pio Zilio; Cosimo Ottomano; Roberto Marchioli; Ivan Cuccovillo; Barbara Bottazzi; Alberto Mantovani; Alessandro Rambaldi
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

3.  Hematologic variables and venous thrombosis: red cell distribution width and blood monocyte count are associated with an increased risk.

Authors:  Suely Meireles Rezende; Willem M Lijfering; Frits R Rosendaal; Suzanne C Cannegieter
Journal:  Haematologica       Date:  2013-07-26       Impact factor: 9.941

4.  Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.

Authors:  Alessandra Carobbio; Alberto Ferrari; Arianna Masciulli; Arianna Ghirardi; Giovanni Barosi; Tiziano Barbui
Journal:  Blood Adv       Date:  2019-06-11

5.  Neutralize the neutrophils! Neutrophil β1/β2 integrin activation contributes to JAK2-V617F-driven thrombosis.

Authors:  Stephen T Oh
Journal:  J Clin Invest       Date:  2018-08-27       Impact factor: 14.808

6.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

7.  Cerebral Venous Thrombosis and Venous Infarction: Case Report of a Rare Initial Presentation of Smoker's Polycythemia.

Authors:  Mihir Raval; Anu Paul
Journal:  Case Rep Neurol       Date:  2010-11-22

8.  Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Authors:  Heinz Gisslinger; Mirjana Gotic; Jerzy Holowiecki; Miroslav Penka; Juergen Thiele; Hans-Michael Kvasnicka; Robert Kralovics; Petro E Petrides
Journal:  Blood       Date:  2013-01-11       Impact factor: 22.113

Review 9.  Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.

Authors:  Brady L Stein; Stephen T Oh; Dmitriy Berenzon; Gabriela S Hobbs; Marina Kremyanskaya; Raajit K Rampal; Camille N Abboud; Kenneth Adler; Mark L Heaney; Elias J Jabbour; Rami S Komrokji; Alison R Moliterno; Ellen K Ritchie; Lawrence Rice; John Mascarenhas; Ronald Hoffman
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

Review 10.  Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.

Authors:  Alessandro M Vannucchi
Journal:  Intern Emerg Med       Date:  2009-09-30       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.